Results 1 to 10 of about 4,586,589 (282)

Metabolism as a biomarker for treatment success in anti-amyloid therapy: A case report [PDF]

NeuroImage: Reports
This case report investigates the potential use of metabolism as a sensitive biomarker in monitoring the effectiveness of anti-amyloid therapy in a patient with mild cognitive impairment due to early Alzheimer's disease.
Kirk C. Wilhelmsen, Pierre-François D’Haese, Marc W. Haut, Gary D. Marano, Rashi I. Mehta, Xiaofei Wang, Melanie Ward, Mark Miller, Umer Najib, R. Osvaldo Navia, Cierra M. Keith, Ali Rezai   +11 more
doaj   +5 more sources

Real-world anti-amyloid therapy beyond traditional symptomatic populations: a longitudinal case series [PDF]

Frontiers in Psychiatry
IntroductionAnti-amyloid monoclonal antibodies are approved as disease-modifying therapies for early Alzheimer’s disease (AD), but real-world evidence remains limited, particularly among individuals treated during preclinical or minimally symptomatic ...
Jayoung Han, Yuan Fang, Darlingtina Esiaka, Olufunmilola Abraham   +3 more
doaj   +3 more sources

Anti-Amyloid Therapy, AD, and ARIA: Untangling the Role of CAA. [PDF]

J Clin Med, 2023
Anti-amyloid therapies (AATs), such as anti-amyloid monoclonal antibodies, are emerging treatments for people with early Alzheimer’s disease (AD). AATs target amyloid β plaques in the brain. Amyloid-related imaging abnormalities (ARIA), abnormal signals seen on magnetic resonance imaging (MRI) of the brain in patients with AD, may occur spontaneously ...
Sin MK, Zamrini E, Ahmed A, Nho K, Hajjar I.   +4 more
europepmc   +5 more sources

Are we ready to use anti-amyloid therapy in Alzheimer's disease? [PDF]

Arquivos de Neuro-Psiquiatria, 2022
Alzheimer’s disease (AD) is the most common neurodegenerative disease. Biomarkers have demonstrated that AD pathology exists over the disease continuum from a stage preceding symptoms over 15-25 years to the progressively more impaired symptomatic states,
Sonia Maria Dozzi Brucki, Karolina Gouveia César-Freitas, Raphael Ribeiro Spera, Conrado Regis Borges, Jerusa Smid   +4 more
doaj   +6 more sources

Aging modulates amyloid clearance kinetics during anti-amyloid therapy: evidence from real-world serial amyloid PET [PDF]

Frontiers in Aging Neuroscience
BackgroundAnti-amyloid antibodies have been shown to reduce cerebral amyloid burden in early Alzheimer’s disease (AD), yet considerable interindividual variability in treatment-associated amyloid reduction has been observed.
Tomomichi Iizuka, Toshiaki Watanabe, Masashi Kameyama   +2 more
doaj   +2 more sources

Longitudinal patterns of regional cerebral blood flow during anti-amyloid therapy in mild cognitive impairment: a pilot ASL MRI case series [PDF]

Frontiers in Aging Neuroscience
IntroductionThe neurovascular effects of anti-amyloid therapy remain incompletely understood. Arterial spin labeling (ASL) MRI enables non-invasive quantification of regional cerebral blood flow (rCBF) and may provide insight into perfusion patterns ...
Eva Y. W. Cheung, Yat Fung Shea, Patrick K. C. Chiu, Koon Ho Chan, Hui Zhang, Ka Keung Yam, Kyongtae T. Bae, Henry K. F. Mak   +7 more
doaj   +2 more sources

Reversing Alzheimer's disease dementia with clemastine, fingolimod, or rolipram, plus anti‐amyloid therapy [PDF]

Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 2022
A few anti‐amyloid trials offer a slight possibility of preventing progression of cognitive loss, but none has reversed the process. A possible reason is that amyloid may be necessary but insufficient in the pathogenesis of AD, and other causal factors ...
Jeffrey Fessel
doaj   +2 more sources

Perspectives on the clinical use of anti‐amyloid therapy for the treatment of Alzheimer's disease: Insights from the fields of cancer, rheumatology, and neurology [PDF]

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Introduction The advent of disease‐modifying therapies for Alzheimer's disease (AD) has raised many questions and debates in the field as to the clinical benefits, risks, and costs of such therapies. The controversies have resulted in the perception that
Gregory A. Jicha, Erin L. Abner, Elif P. Coskun, Mark J. Huffmyer, Thomas C. Tucker, Peter T. Nelson   +5 more
doaj   +2 more sources

Anti‐amyloid therapy eligibility in a longitudinal brain‐donor cohort with post mortem confirmation [PDF]

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring
INTRODUCTION Anti‐amyloid therapies (AATs) for Alzheimer's disease (AD) demonstrate modest benefit in trials, but real‐world eligibility remains uncertain. Requirements including biomarker confirmation and safety exclusions may limit access.
Monjurul Haque, Keeley J. Brookes, Beili Shao   +2 more
doaj   +2 more sources

Quantitative systems pharmacology‐based exploration of relevant anti‐amyloid therapy challenges in clinical practice [PDF]

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION Addressing practical challenges in clinical practice after the recent approvals of amyloid antibodies in Alzheimer's disease (AD) will benefit more patients.
Hugo Geerts, Silke Bergeler, Mike Walker, Rachel H. Rose, Piet H. van derGraaf   +4 more
doaj   +2 more sources